Archive for March, 2012
Vibex MTX is the Most Exciting Component of the Antares Investment Outlook (AIS, $2.74)
Investment Thesis I initiated coverage of Antares (AIS) on December 8, 2011 with a buy rating. Important factors driving my recommendation were its broad based relationship with Teva for developing injectable pharmaceuticals and the recently approved Anturol, a gel based product for urinary incontinence. I also felt that LibiGel could be a meaningful, but not […]